Lifeward files initial beneficial ownership statement for director Moshe H. Rozenbaum

Lifeward appoints Rozenbaum, Sigsbee, Reznick to audit committee, regains Nasdaq compliance

Oramed completes Oratech sale to Lifeward for shares, warrants, revenue-sharing payments

Lifeward files initial beneficial ownership statement; director Miriam Kidron reports no securities beneficially owned

Lifeward closes strategic partnership agreement with Oramed

Lifeward issues $10 million senior secured convertible notes; private placement includes 2,256,476 ordinary shares and pre-funded warrants

Lifeward closes strategic partnership with Oramed; access to capital grows to $47 million

Lifeward receives Nasdaq notice over audit committee non-compliance under Listing Rule 5605(c)(2)(A)

Lifeward Is Maintained at Buy by HC Wainwright & Co.

Lifeward Ltd : H.c. Wainwright Raises Target Price to $10 From $4.5

Lifeward price target adjusted to $10 from $4.50 at H.C. Wainwright

Lifeward Ltd reports results for the quarter ended December 31 - Earnings Summary

Lifeward Q4 revenue fell 33% to USD 5.08 million as net loss narrowed 65% to USD 5.35 million

Lifeward Q4 Adj. EPS $(2.85) Misses $(1.08) Estimate, Sales $5.081M Miss $7.861M Estimate

Press Release: Lifeward Reports Fourth Quarter and Full Year 2025 Financial Results

Lifeward Ltd expected to post a loss of $1.08 a share - Earnings Preview

Lifeward Ltd. Held Shareholder Meeting

Lifeward to partner with Oramed in deal providing access to up to USD 47 million

Lifeward Regains Nasdaq Minimum Bid Price Compliance

Lifeward Ltd. to Report Q4 and Full-Year 2025 Financial Results